Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

NovaBridge Biosciences

NASDAQ NBP
$4.23 0.04 0.95%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 13.75 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
197.71M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
33.16M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
81.70M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
397.65 %

Upcoming events NovaBridge Biosciences

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart NovaBridge Biosciences

Stock analysis NovaBridge Biosciences

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-5.17 -1.68
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
0.34 1.67
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-1.05 -1.11
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
5.20 0.40
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-19.42 -50.04

Price change NovaBridge Biosciences per year

0.62$ 6.56$
Min Max

Summary analysis NovaBridge Biosciences

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure NovaBridge Biosciences

Revenue and net income NovaBridge Biosciences

All parameters

About company NovaBridge Biosciences

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Address:
2440 Research Boulevard, Rockville, MD, United States, 20850
Company name: NovaBridge Biosciences
Issuer ticker: NBP
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2020-01-17
Sector: Healthcare
Industry: Biotechnology
Site: https://www.i-mabbiopharma.com